Ana Ochoa-Guzmán
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Ochoa-Guzmán has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Erwin Chiquete
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
7 shared publications - Carlos Cantú-Brito
Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
4 shared publications - Liz Toapanta-Yanchapaxi
Department of Neurology, National Institute of Medical Sciences and Nutrition Salvador Zubirán
3 shared publications - Adrián Garcilazo-Ávila
Experimental Research Unit, Faculty of Medicine, National Autonomous University of Mexico (UNAM), Mexico City (J.A.-D., P.B., J.A.G.-A., C.G.-C., R.R.-R., F.R., J.B.).
2 shared publications - Carlos González-Carballo
Experimental Research Unit, Faculty of Medicine, National Autonomous University of Mexico (UNAM) , Mexico City
2 shared publications - Eduardo Ruiz-Ruiz
Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, CDMX, México
2 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (12)
Genotype and visceral adiposity interactions on hepatic steatosis in Mexican adults
Background: The SLC16A11 haplotype has been associated with type 2 diabetes (T2D) in populations with high Native American ancestry; however, its role in hepatic outcomes remains uncertain. We evaluated the association of rs13342232 with noninvasive liver markers and whether visceral adiposity tissue (VAT) modifies this relationship in Mexican adults with and without T2D. Methods: We included 607 adults (non-T2D, n = 256; T2D, n = 351) with genotype, VAT, and fatty liver index (FLI) data. Hepatic steatosis was additionally assessed using FibroScan-derived controlled attenuation parameter and steatosis grade in 301 participants. Multivariable regression models with VAT × rs13342232 interaction terms were fitted, adjusting for ancestry principal components. Results: A significant VAT × G/G interaction on FLI was observed in the full sample (β = 3.19, 95% CI 0.23-6.15; P = .035). The interaction was markedly stronger in adults without T2D (β = 7.51, 95% CI 1.23-13.78; P = .018) than in those with T2D (β = 2.00, 95% CI −0.43 to 4.42; P = .105), suggesting that the gene–environment effect is most clearly expressed before diabetes onset. Null findings for both the A/G interaction and the dominant model in the non-T2D stratum support a recessive inheritance pattern. FibroScan validation confirmed a VAT × G/G interaction on steatosis grade in non-T2D participants (β = .50, 95% CI 0.01-0.99; P = .044). In the T2D stratum, a significant negative A/G × VAT interaction was observed (β = −1.63, P = .046), indicating heterozygote attenuation of the VAT–steatosis relationship. Conclusion: The SLC16A11 rs13342232 G/G genotype amplifies the hepatic steatosis response to visceral adiposity in Mexican adults. This effect is strongest prior to diabetes onset, supporting a gene–environment interaction in hepatic fat accumulation.
- 27 October 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (12)
Open AccessGenotype and visceral adiposity interactions on hepatic steatosis in Mexican adults
Background: The SLC16A11 haplotype has been associated with type 2 diabetes (T2D) in populations with high Native American ancestry; however, its role in hepatic outcomes remains uncertain. We evaluated the association of rs13342232 with noninvasive liver markers and whether visceral adiposity tissue (VAT) modifies this relationship in Mexican adults with and without T2D. Methods: We included 607 adults (non-T2D, n = 256; T2D, n = 351) with genotype, VAT, and fatty liver index (FLI) data. Hepatic steatosis was additionally assessed using FibroScan-derived controlled attenuation parameter and steatosis grade in 301 participants. Multivariable regression models with VAT × rs13342232 interaction terms were fitted, adjusting for ancestry principal components. Results: A significant VAT × G/G interaction on FLI was observed in the full sample (β = 3.19, 95% CI 0.23-6.15; P = .035). The interaction was markedly stronger in adults without T2D (β = 7.51, 95% CI 1.23-13.78; P = .018) than in those with T2D (β = 2.00, 95% CI −0.43 to 4.42; P = .105), suggesting that the gene–environment effect is most clearly expressed before diabetes onset. Null findings for both the A/G interaction and the dominant model in the non-T2D stratum support a recessive inheritance pattern. FibroScan validation confirmed a VAT × G/G interaction on steatosis grade in non-T2D participants (β = .50, 95% CI 0.01-0.99; P = .044). In the T2D stratum, a significant negative A/G × VAT interaction was observed (β = −1.63, P = .046), indicating heterozygote attenuation of the VAT–steatosis relationship. Conclusion: The SLC16A11 rs13342232 G/G genotype amplifies the hepatic steatosis response to visceral adiposity in Mexican adults. This effect is strongest prior to diabetes onset, supporting a gene–environment interaction in hepatic fat accumulation.
- Open Access
- 29 May 2022
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (1) , 67-74
Analysis on Cause-Specific Atherothrombotic Cardiovascular Disease Mortality in Mexico: 2011-2015
Introduction: In Mexico, cardiovascular disease (CVD) represents the most important cause of mortality and disability. We aimed to analyze the mortality rate due to specific causes of atherothrombotic CVD from 2011 to 2015. Material and methods: We analyzed 3,105,975 death certificates...
- 29 May 2022
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (1) , 67-74
Open AccessAnalysis on Cause-Specific Atherothrombotic Cardiovascular Disease Mortality in Mexico: 2011-2015
Introduction: In Mexico, cardiovascular disease (CVD) represents the most important cause of mortality and disability. We aimed to analyze the mortality rate due to specific causes of atherothrombotic CVD from 2011 to 2015. Material and methods: We analyzed 3,105,975 death certificates...
- 13 January 2022
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (4) , 2217-2229
Critical role of acute hypoxemia on the cognitive impairment after severe COVID-19 pneumonia: a multivariate causality model analysis
Background A high proportion of coronavirus disease 2019 (COVID-19) survivors may develop long-term cognitive impairment. We aimed to develop a multivariate causal model exposing the links between COVID-19-associated biomarkers, illness-related variables, and their effects on cognitive performance. Methods In this prospective study, we assess the potential drivers for the development of cognitive impairment in patients with severe COVID-19 pneumonia aged ≥ 18 years at 6-month follow-up after hospital discharge, using the Montreal Cognitive Assessment (MoCA). Patients with pre-existing cognitive impairment were excluded. Laboratory results at hospital admission were clustered by principal component analysis (PCA) and included in a path analysis model evaluating the causal relationship between age, comorbidities, hypoxemia, invasive mechanical ventilation (IMV) requirement, in-hospital delirium, and cognitive performance. Results We studied 92 patients: 54 (58.7%) men and 38 (41.3%) women, with median age of 50 years (interquartile range 42–55), among whom 50 (54.4%) tested positive for cognitive impairment at 6-month follow-up. Path analysis revealed a direct link between the thrombo-inflammatory component of PCA (C-reactive protein, fibrinogen, and neutrophils) and hypoxemia severity at hospital admission. Our model showed that low PaO2/FiO2 ratio values, unlike the thrombo-inflammatory component, had a direct effect on cognitive performance, independent from age, in-hospital delirium, and invasive mechanical ventilation. Conclusion In this study, biomarkers of thrombo-inflammation in COVID-19 and low PaO2/FiO2 had a negative effect on cognitive performance 6 months after hospital discharge. These results highlight the critical role of hypoxemia as a driver for impaired cognition in the mid-term.
- 13 January 2022
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (4) , 2217-2229
Critical role of acute hypoxemia on the cognitive impairment after severe COVID-19 pneumonia: a multivariate causality model analysis
Background A high proportion of coronavirus disease 2019 (COVID-19) survivors may develop long-term cognitive impairment. We aimed to develop a multivariate causal model exposing the links between COVID-19-associated biomarkers, illness-related variables, and their effects on cognitive performance. Methods In this prospective study, we assess the potential drivers for the development of cognitive impairment in patients with severe COVID-19 pneumonia aged ≥ 18 years at 6-month follow-up after hospital discharge, using the Montreal Cognitive Assessment (MoCA). Patients with pre-existing cognitive impairment were excluded. Laboratory results at hospital admission were clustered by principal component analysis (PCA) and included in a path analysis model evaluating the causal relationship between age, comorbidities, hypoxemia, invasive mechanical ventilation (IMV) requirement, in-hospital delirium, and cognitive performance. Results We studied 92 patients: 54 (58.7%) men and 38 (41.3%) women, with median age of 50 years (interquartile range 42–55), among whom 50 (54.4%) tested positive for cognitive impairment at 6-month follow-up. Path analysis revealed a direct link between the thrombo-inflammatory component of PCA (C-reactive protein, fibrinogen, and neutrophils) and hypoxemia severity at hospital admission. Our model showed that low PaO2/FiO2 ratio values, unlike the thrombo-inflammatory component, had a direct effect on cognitive performance, independent from age, in-hospital delirium, and invasive mechanical ventilation. Conclusion In this study, biomarkers of thrombo-inflammation in COVID-19 and low PaO2/FiO2 had a negative effect on cognitive performance 6 months after hospital discharge. These results highlight the critical role of hypoxemia as a driver for impaired cognition in the mid-term.
- 1 February 2021
- Published by Elsevier in Archives of Medical Research
- Vol. 52 (2) , 233-239
Obesity Paradox and 12 Month Outcome in Patients with Atrial Fibrillation
- 1 February 2021
- Published by Elsevier in Archives of Medical Research
- Vol. 52 (2) , 233-239
Obesity Paradox and 12 Month Outcome in Patients with Atrial Fibrillation
- Open Access
- 4 December 2020
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 18 (3) , 711-718
Ethnicity and other COVID-19 death risk factors in Mexico
Introduction: Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may develop coronavirus disease 2019 (COVID-19). Risk factors associated with death vary among countries with different ethnic backgrounds. We aimed to describe the factors associated with death in Mexicans with confirmed COVID-19.Material and methods: We analysed the Mexican Ministry of Health’s official database on people tested for SARS-CoV-2 infection by real-time reverse transcriptase–polymerase chain reaction (rtRT-PCR) of nasopharyngeal fluids. Bivariate analyses were performed to select characteristics potentially associated with death, to integrate a Cox-proportional hazards model.Results: As of May 18, 2020, a total of 177,133 persons (90,586 men and 86,551 women) in Mexico received rtRT-PCR testing for SARS-CoV-2. There were 5332 deaths among the 51,633 rtRT-PCR-confirmed cases (10.33%, 95% CI: 10.07–10.59%). The median time (interquartile range, IQR) from symptoms onset to death was nine days (5–13 days), and from hospital admission to death 4 days (2–8 days). The analysis by age groups revealed that the significant risk of death started gradually at the age of 40 years. Independent death risk factors were obesity, hypertension, male sex, indigenous ethnicity, diabetes, chronic kidney disease, immunosuppression, chronic obstructive pulmonary disease, age > 40 years, and the need for invasive mechanical ventilation (IMV). Only 1959 (3.8%) cases received IVM, of whom 1893 were admitted to the intensive care unit (96.6% of those who received IMV).Conclusions: In Mexico, highly prevalent chronic diseases are risk factors for death among persons with COVID-19. Indigenous ethnicity is a poorly studied factor that needs more investigation.
- 4 December 2020
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 18 (3) , 711-718
Open AccessEthnicity and other COVID-19 death risk factors in Mexico
Introduction: Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may develop coronavirus disease 2019 (COVID-19). Risk factors associated with death vary among countries with different ethnic backgrounds. We aimed to describe the factors associated with death in Mexicans with confirmed COVID-19.Material and methods: We analysed the Mexican Ministry of Health’s official database on people tested for SARS-CoV-2 infection by real-time reverse transcriptase–polymerase chain reaction (rtRT-PCR) of nasopharyngeal fluids. Bivariate analyses were performed to select characteristics potentially associated with death, to integrate a Cox-proportional hazards model.Results: As of May 18, 2020, a total of 177,133 persons (90,586 men and 86,551 women) in Mexico received rtRT-PCR testing for SARS-CoV-2. There were 5332 deaths among the 51,633 rtRT-PCR-confirmed cases (10.33%, 95% CI: 10.07–10.59%). The median time (interquartile range, IQR) from symptoms onset to death was nine days (5–13 days), and from hospital admission to death 4 days (2–8 days). The analysis by age groups revealed that the significant risk of death started gradually at the age of 40 years. Independent death risk factors were obesity, hypertension, male sex, indigenous ethnicity, diabetes, chronic kidney disease, immunosuppression, chronic obstructive pulmonary disease, age > 40 years, and the need for invasive mechanical ventilation (IMV). Only 1959 (3.8%) cases received IVM, of whom 1893 were admitted to the intensive care unit (96.6% of those who received IMV).Conclusions: In Mexico, highly prevalent chronic diseases are risk factors for death among persons with COVID-19. Indigenous ethnicity is a poorly studied factor that needs more investigation.
- Open Access
Risk of infection and hospitalization by Covid-19 in Mexico: a case-control study
Objective. During the onset of a novel epidemic, there are public health priorities that need to be estimated, such as risk factors for infection, hospitalization, and clinical severity to allocate resources and issue health policies. In this work we calculate the risk of infection and hospitalization by Covid-19 conferred by demographic, lifestyle, and co-morbidity factors. Material and methods. This is a case-control study including the tested individuals for SARS-Cov-2 by RT-PCR officially reported by the Health Secretary of Mexico from January 01 to May 8, 2020 (102,875 subjects). Demographic (sex, age, foreign and immigrant status, native speaking, place of residence), life-style (smoking), and co-morbidities [diabetes, obesity, high blood pressure (HBP), asthma, immunosuppression, chronic obstructive pulmonary disease (COPD), cardiovascular disease other than HBP, chronic kidney disease (CKD), and other not specified diseases (other diseases)] variables were included in this study. The risk of infection and hospitalization conferred by each variable was calculated with univariate (ULR) and multivariate (MLR) logistic regression models. Results. The place of residence (OR=4.91 living in Tijuana City), followed by advanced age (OR=6.71 in 61-70 years-old), suffering from diabetes (OR=1.87) or obesity (OR=1.61), being male (OR=1.55), having HBP (OR=1.52), and notoriously being indigenous (OR=1.49) conferred a higher risk of becoming infected by SARS-CoV-2 in Mexico. Unexpectedly, we found that having asthma (OR=0.63), immunosuppression (OR=0.65) or smoking (OR=0.85) are protective factors against infection, while suffering from COPD does not increase the risk for SARS-CoV-2 infection. In contrast, advanced age (OR=11.6 in ≥ 70 years-old) is the main factor for hospitalization due to Covid-19, followed by some co-morbidities, mainly diabetes (OR=3.69) and HBP (OR=2.79), being indigenous (OR=1.89), male sex (OR=1.67) and the place of residence (OR=4.22 for living in Juarez City). Unlike the protective risk against infection, immunosuppression (OR=2.69) and COPD (OR=3.63), contribute to the risk of being hospitalized, while having asthma (OR=0.7) also provides protection against hospitalization. Conclusions. In addition to confirming that older age, diabetes, HBP and obesity are the main risk of infection and hospitalization by Covid-19, we found that being indigenous, immunosuppression, smoking and asthma protect against infection, and the latter also against hospitalization.
Open AccessRisk of infection and hospitalization by Covid-19 in Mexico: a case-control study
Objective. During the onset of a novel epidemic, there are public health priorities that need to be estimated, such as risk factors for infection, hospitalization, and clinical severity to allocate resources and issue health policies. In this work we calculate the risk of infection and hospitalization by Covid-19 conferred by demographic, lifestyle, and co-morbidity factors. Material and methods. This is a case-control study including the tested individuals for SARS-Cov-2 by RT-PCR officially reported by the Health Secretary of Mexico from January 01 to May 8, 2020 (102,875 subjects). Demographic (sex, age, foreign and immigrant status, native speaking, place of residence), life-style (smoking), and co-morbidities [diabetes, obesity, high blood pressure (HBP), asthma, immunosuppression, chronic obstructive pulmonary disease (COPD), cardiovascular disease other than HBP, chronic kidney disease (CKD), and other not specified diseases (other diseases)] variables were included in this study. The risk of infection and hospitalization conferred by each variable was calculated with univariate (ULR) and multivariate (MLR) logistic regression models. Results. The place of residence (OR=4.91 living in Tijuana City), followed by advanced age (OR=6.71 in 61-70 years-old), suffering from diabetes (OR=1.87) or obesity (OR=1.61), being male (OR=1.55), having HBP (OR=1.52), and notoriously being indigenous (OR=1.49) conferred a higher risk of becoming infected by SARS-CoV-2 in Mexico. Unexpectedly, we found that having asthma (OR=0.63), immunosuppression (OR=0.65) or smoking (OR=0.85) are protective factors against infection, while suffering from COPD does not increase the risk for SARS-CoV-2 infection. In contrast, advanced age (OR=11.6 in ≥ 70 years-old) is the main factor for hospitalization due to Covid-19, followed by some co-morbidities, mainly diabetes (OR=3.69) and HBP (OR=2.79), being indigenous (OR=1.89), male sex (OR=1.67) and the place of residence (OR=4.22 for living in Juarez City). Unlike the protective risk against infection, immunosuppression (OR=2.69) and COPD (OR=3.63), contribute to the risk of being hospitalized, while having asthma (OR=0.7) also provides protection against hospitalization. Conclusions. In addition to confirming that older age, diabetes, HBP and obesity are the main risk of infection and hospitalization by Covid-19, we found that being indigenous, immunosuppression, smoking and asthma protect against infection, and the latter also against hospitalization.
- Open Access
- 18 April 2019
- Published by Grupo Anltyk S.A. de C.V. in Latin american journal of clinical sciences and medical technology
- Vol. 3 (1) , 90-98
Genes y diabetes mellitus tipo 2
Type 2 diabetes mellitus (T2D) is considered a public health disease that affects the health of millions worldwide. Therefore, the diabetes phenotype that develops an individual is conditioned by inherited DNA risk variants, as well as the response to lifestyle exposure. In this article, we explore the monogenic forms of diabetes, how T2D is the result of the interaction between genes and lifestyle, and some of the methods used to demonstrate the genetic role in diabetes mellitus, through techniques such as linkage analysis, candidate gene studies, and some more recent and innovative studies such as genome-wide association studies, in which more than 400 genetic variants have been associated with T2D across different ethnic groups. Future studies integrating genetic and biological markers are still required to understand this complex disease, and to have access to better treatments.
- 18 April 2019
- Published by Grupo Anltyk S.A. de C.V. in Latin american journal of clinical sciences and medical technology
- Vol. 3 (1) , 90-98
Open AccessGenes y diabetes mellitus tipo 2
Type 2 diabetes mellitus (T2D) is considered a public health disease that affects the health of millions worldwide. Therefore, the diabetes phenotype that develops an individual is conditioned by inherited DNA risk variants, as well as the response to lifestyle exposure. In this article, we explore the monogenic forms of diabetes, how T2D is the result of the interaction between genes and lifestyle, and some of the methods used to demonstrate the genetic role in diabetes mellitus, through techniques such as linkage analysis, candidate gene studies, and some more recent and innovative studies such as genome-wide association studies, in which more than 400 genetic variants have been associated with T2D across different ethnic groups. Future studies integrating genetic and biological markers are still required to understand this complex disease, and to have access to better treatments.
- Open Access
- 8 April 2019
- Published by Grupo Anltyk S.A. de C.V. in Latin american journal of clinical sciences and medical technology
- Vol. 4 (1) , 75-84
Attainment of Best Practice Recommendations and Late Complications of Patients with Type 1 and Type 2 Diabetes Mellitus
- 8 April 2019
- Published by Grupo Anltyk S.A. de C.V. in Latin american journal of clinical sciences and medical technology
- Vol. 4 (1) , 75-84
Open AccessAttainment of Best Practice Recommendations and Late Complications of Patients with Type 1 and Type 2 Diabetes Mellitus